Holen Sie sich die Stockscreener-App
263.18
1.08%
3.2098
Schlusskurs vom Vortag:
$259.97
Offen:
$258.93
24-Stunden-Volumen:
1.92M
Relative Volume:
1.33
Marktkapitalisierung:
$37.66B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-160.36
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+13.56%
1M Leistung:
+29.33%
6M Leistung:
+11.57%
1J Leistung:
+60.08%
1-Tages-Spanne:
$258.50
$271.47
1-Wochen-Bereich:
$219.50
$271.47
52-Wochen-Spanne:
$131.81
$271.47
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
262.98 | 37.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
506.67 | 182.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
194.32 | 133.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
554.70 | 43.32B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.26 | 37.18B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - The Globe and Mail
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar? - Yahoo Finance Singapore
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial - TradingView
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Canada
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Yahoo! Finance Canada
Biotech Medical Test Leader Hits Record High, Joins 15 Others New To Best Stock Lists - Investor's Business Daily
Form 144 NATERA For: 24 June By Investing.com - Investing.com South Africa
[144] Natera, Inc. SEC Filing - Stock Titan
This Medtech Stock Just Flashed A Buy Signal; Here's Why - Investor's Business Daily
Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets - StocksToTrade
NTRA Maintained by BTIG -- Price Target Raised to $275 - GuruFocus
Natera Stock Jumps As NCCN Endorses Signatera MRD Test - timothysykes.com
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Benzinga
Natera (NTRA) Is Up 6.7% After First PMDA-Approved MRD Test in JapanWhat's Changed - simplywall.st
Natera Inc stock hits all-time high at 256.57 USD - Investing.com
Natera Inc stock hits all-time high at 256.57 USD By Investing.com - Investing.com South Africa
Natera stock jumps as investors focus on fresh clinical data and strong growth outlook - Quiver Quantitative
Why Natera (NTRA) Stock Is Up Today - TradingView
Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera - Blockonomi
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $249 to $285 - Moomoo
ETFs Investing in Natera, Inc. Stocks - TradingView
Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer - Yahoo Finance
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer - Business Wire
Natera Secures Japan Clearance for Signatera Test for Colorectal Cancer - Moomoo
Natera (NTRA) Teams With Pirche To Link Transplant Risk And Prospera Monitoring - Yahoo Finance
Natera receives Japan regulatory approval for cancer test - Investing.com
Natera receives Japan regulatory approval for cancer test By Investing.com - Investing.com South Africa
Why Is Natera Stock Gaining Tuesday? - Sahm
Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer - TradingView
Natera (NTRA) Gains NCCN Recognition for Tumor-Informed ctDNA Te - GuruFocus
NTRA Maintained by BTIG -- Price Target Raised to $270 - GuruFocus
Natera stock price target raised to $270 by BTIG on guidelines win - Investing.com Nigeria
Natera stock price target raised to $270 by BTIG on guidelines win By Investing.com - Investing.com South Africa
NTRA Technical Analysis & Stock Price Forecast - Intellectia AI
Natera options trading jumps with focus on July calls By Investing.com - Investing.com Canada
Natera options trading jumps with focus on July calls - Investing.com
Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care - AJMC
Natera (NTRA) Stock Fair Value Edges Lower As MRD And Signatera Debate Splits Analysts - Yahoo Finance
Natera’s Signatera receives NCCN Category 1 recommendation - Investing.com UK
Natera’s Signatera receives NCCN Category 1 recommendation By Investing.com - Investing.com Australia
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update - Business Wire
Natera wins Japan approval for Signatera colorectal test - grafa.com
Natera co-founder Sheena Jonathan sells $329,809 in company stock By Investing.com - Investing.com Australia
Natera co-founder Sheena Jonathan sells $329,809 in company stock - Investing.com UK
Signatera (NTRA) Gains Momentum with New NCCN Bladder Cancer Gui - GuruFocus
Form 4 Natera Inc For: 22 June By Investing.com - Investing.com Canada
Natera (NTRA) co-founder’s family trusts sell 1,500 shares under 10b5-1 plan - Stock Titan
Natera expands Austin operations with new sequencing facility - MSN
Leerink Partners Maintains Natera(NTRA.US) With Buy Rating - Moomoo
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):